Indian biopharmaceutical giant Biocon has announced the full integration of its biosimilar unit, Biocon Biologics, consolidating all of its biosimilars and generics operations under one unified entity. This move aims to streamline operations, strengthen Biocon’s presence in global biosimilars markets, and enhance value creation for shareholders.
As part of the integration, Biocon will acquire the remaining stakes in Biocon Biologics currently held by Serum Institute Life Sciences, Tata Capital Growth Fund II, and Activ Pine LLP. The acquisition will be executed through a share swap arrangement, where 70.28 Biocon shares will be exchanged for every 100 Biocon Biologics shares, at a price of 405.78 rupees (approximately US$4.51) per Biocon share. The transaction values Biocon Biologics at a substantial US$5.5 billion.
Following the integration, Biocon Biologics’ CEO Shreehas Tambe will take the helm as CEO and managing director of the newly consolidated entity, while Kedar Upadhye will serve as chief financial officer. Biocon CEO Siddharth Mittal will transition to a broader group leadership role, overseeing strategic growth and global operations. The integration is expected to be completed by March 31, 2026.
The Bengaluru-based company said it evaluated several options for Biocon Biologics, including an initial public offering (IPO) and a merger, before concluding that acquiring minority stakes through a share swap would be the most efficient and value-accretive approach. According to Tambe, the company may still pursue a listing of its key biosimilars business by March 2026 and aims to secure a double-digit market share in the US for its upcoming launches.
Biosimilars are cost-effective alternatives to expensive and complex biologics, which are used to treat conditions such as cancer, autoimmune diseases, and other chronic illnesses. By integrating Biocon Biologics, Biocon expects to leverage operational efficiencies, strengthen its product pipeline, and accelerate growth in key international markets.
In a related development, Biocon also plans to acquire the remaining stake in its previously acquired biosimilars business Viatris for US$815 million, of which US$400 million will be paid in cash and US$415 million via a share swap. To facilitate the cash component of the transaction, the company has approved raising up to 45 billion rupees (approximately US$500 million) through a Qualified Institutional Placement (QIP).
This series of strategic moves reflects Biocon’s focus on consolidating its biosimilars and generics operations, strengthening its balance sheet, and positioning the group for sustainable growth in the high-value global biologics market. The combined entity is expected to deliver enhanced financial performance, operational efficiency, and a more robust platform for international expansion, solidifying Biocon’s status as a leading player in the biosimilars industry.
